The Psychiatric Clinics of North America 1997: Vol 20 Index

29 Pages·1997·6.6 MB·English

CUMULATIVE INDEX 1997
Volume 20
March GERIATRIC PSYCHIATRY: WHAT’S NEW ABOUT
THE OLD, pages 1-268
June ANGER, AGGRESSION, AND VIOLENCE, pages 269-498
September SUICIDE, pages 499-690
December NEUROPSYCHIATRY OF THE BASAL
GANGLIA, pages 691-991
Note: Page numbers of article titles are in boldface type
Absorption, of drug, aging and, 215-216 violence in, late-starting, 288-289
Abuse, child, 280, 358-369, 480-481 males versus females, 272-273, 278
elder, 276-277, 357-358, 482-483 rate increase in, 271-272, 277-278
emotional, in battering relationships, Adolescents, aggressivity of, adverse
347-348, 353 factors in adoptee home and, 310
of developmentally disabled, 481482 by Family Environment Scale, conflict
sexual, 355, 480-482 scale in, 313-314
verbal, 305, 341, 346 expressiveness scale in, 312, 314-316
Activity programming, in behavior effect on home enviroment, 309,
therapy, 462 311-312
Adaptation, diminished in dementia, 228 prediction of, genetic-environmental
ADAS. See Alzheimer’s Disease Assessment interaction in, 316
Scale (ADAS). antidepressants in, response to, 651-653
Addictive disorders, suicide risk and, suicidal behavior of, fluoxetine in, 654—
506-506 658
Adjustment disorders, late-life, in DSM-IV, hospitalization of, 645-648
12 outpatient treatment of, 647
Adolescence, aggression in, limited, intensive case management in, 647-
288-289, 292 648
prognosis of, 289 noncompliance with, 647
verbal, measurement of, 305 pharmacotherapy for, 650-660
aggressive and violent behaviors in, program development and testing for,
crime records of, 303, 305 problems in, 648-649
evaluation and questionnaire for, 303- serotonin reuptake inhibitors for, 655-
304 660. See also Fluoxetine.
observation of, 303, 305 treatment of, psychotherapeutic, 649-
sibling studies of, 304 650
attention deficit/hyperactivity disorder tricyclic antidepressants for, 650-651
in, psychopharmacotherapy for, lithium augmentation of, 653-654
436438 mania with, 654
suicide in, attempted, 641 response to, 651-653
demographic factors and, 559 women, marital violence effect on, 362
rates of, 642 Adoption studies, of suicidal behavior,
completed, risk factors for, 642-643 603-605
963
964 CUMULATIVE INDEX 1997
Adoption studies (Continued) emotional, 341, 376
in relatives of adoptees, 603-605 environmental stress and, 387-388
Adrenergic system, aging and, psychophysiology relationship to,
pharmacodynamics of, 213-215 384-388
Adults, aggressive and violent behavior in, evaluation of, by proactive versus reac-
crime records of, 307-308 tive aggression children, 295
genetic component of, 305-307 family interaction and, 289-292
interaction of genetics and attachment perspective in, 289-290
environment in, 307 coercion model of, 290-291
questionnaire for, 305-306 process in, reciprocal, 290-291
Affect, negative, in battering relationships, indiscriminate, 291
346-347 parental monitoring in, 291-292
Affective disorders, suicide in, family power assertive discipline in, 290
history of suicide and, 597 gender differences in, biologic versus so-
suicide risk factors in, alcohol depen- cial mediation, 287
dence, 621 physical versus relational, 287
Amish study of, 599-600 hostile, 375-376
borderline personality disorder, 621 impulsive, 395-403
for bipolar disorder, 620-621 individual differences in, life-course pat-
African-Americans, versus whites, terns and, 288-289
homicide rate in, 273-274, 278 instrumental, 375
violence and, criminal, 279 life-course persistent, 288-289, 292
prediction of, self-reporting likelihood negative emotionality and, 385-386
ratios and, 327 neurobiology of. See Neurobiology, of im-
Age, in DSM-IV classes and diagnoses, pulsive aggression.
infancy, childhood, adolescence, 2 pathologic. See also Pathologic aggression.
in violence prediction, 325-326 psychopharmacologic treatment of,
suicide and, attempted, 505-506 427-451
completed, 502 peer relationships and, 292-293
violent behavior and, increase in, 271- proactive versus reactive, in children,
272 295
Aggression. See also Aggressive and violent proactive /instrumental, 375
behavior; Aggressive and violent patient; reactive/hostile, 375-376
Violence. stability of, 288-289
adolescent-limited, 288-289, 292 suicidal behavior and, 630-631
antisocial behavior and, 284 verbal, in adolescents, 305
behavioral, definition of, 301 Aggressive and violent behavior,
prevalence of, 395 aggression gene for, historical
definitions of, 283-285, 301 perspective on, 316-317
biologic predisposition and, 395-396 aggressivity symptoms-adverse factors
effects in, 284 in adoptive home, 308-310
intentionality in, 284 contribution genetic-environmental inter-
proactive versus reactive, 285, 295, action in, in childhood and adoles-
375-376 cence, 308-316
development of, elicitors in, 286 genetics of, 301-322
family interactions in, 289-292 cross-generational stability of, 307
gender differences in, 286-287 molecular biology and, 316-319
individual differences in, 288-289 neurotransmitter systems in, 317-319
transactional perspective on, 296- prevention of, genetic-environmental in-
297 teraction in, 319-320
normative, 285-287 Aggressive and violent patient,
peer relationships in, 292-293 psychotherapeutic approaches to,
physical, 285-286 453-472. See also Psychotherapy, with
psychological, 286 aggressive and violent patients.
social information-processing patterns Aggressive conduct disorder, in children
in, 293-296 and adolescents, psychopharma-
social-cognitive mechanisms in, 293- cotherapy for, 436-438
296 Aging, cerebral, in Parkinson's disease,
verbal and hostile, 285-286 772-773
emotion regulation and, 386-387 grief effect on, 22-23
CUMULATIVE INDEX 1997 965
in DSM-IV, 2 Amyloid precursor protein (APP), in
neurobiologic changes in, as suicide risk dementia of Alzheimer’s type, 62,
factor, 668-669 83-84
normal, as concept, 15-17 Androgenic steroids, in pathogenesis of
cognitive changes in, 20-22, 26 Tourettes’s syndrome, 850
cross-sectional versus longitudinal Androgens, aggressive behavior and,
studies of, 1-16 396-397
personal history and culture in, 16-17 Anger, and violent behavior,
personality changes in, 18-19 psychophysiology of, 375-394
physical functioning in, 17 irritability and, in premenstrual dys-
sensory abilities in, 17-18 phoric disorder, psychopharmaco-
sexual functioning in, 19-20 therapy for, 441
sleep in, 18 Anger, Irritability, Aggression
pharmacodynamic changes with, 212- Questionnaire, 430
215 Anger, Irritability, Assault Questionnaire,
psychology of normal, 15-24 458-459
sleep and, age-related changes in, 147- Anger and hostility, in violent versus
148 nonviolent men, 340-341
Agitation, definition of, 226 Anger Attacks Questionnaire, 430, 458
in demented elderly, antidepressants for, Anti-amyloid agents, for dementia of
236-237 Alzheimer’s type, 86-87
anxiolytics for, 238 Anticholinergic drugs, in dystonia,
behavioral interventions for, 233-234 generalized, 830
diagnosis of causes of, 231 in Parkinson's disease, 784
environmental modification for, 234 Anticonvulsant drugs, for pathologic
family and, 234-235 aggression, 442-443
medications for, 235-238 in children and adolescents, 437
use and misuse of, 235-236 in mentally retarded patients, 436
mood stabilizers for, 237 in organic brain syndromes, 434
neuroleptics for, 237 in schizophrenia and psychoses,
in dementia, 227-228 438-439, 439
models for, characterologic, 229-230 post brain injury, 434
diminished adaptive capacity, 228 Antidepressants, for agitation in dementia,
neurobiologic, 230 236-237
stress, 228-229 in adolescence, efficacy of, diminished,
treatment plan development for, 232 654
Akathisia, with selective serotonin- in geriatric patients, for insomnia, 159
reuptake inhibitors, 618 for obsessive-compulsive disorder,
Akinesia, in Parkinson's disease, 774-775 142, 145
Alcohol abuse. See also Substance and in primary care, 254
alcohol abuse. in obsessive-compulsive disorder, 872-
in domestically violent men, 330 873
late-life, in DSM-IV, 5-6 in suicidal patient, dosage of, 619
prevalence in primary care, 245 initiation of therapy with, suicide risk
suicide and, in adolescents, 645 with, 617-618
violence and, 343 mania with, 654
prediction of, 329 side effects and suicidality with, 618
risk for, 476 studies with suicidal patients, noradren-
Alcohol dependence, suicide risk in, 621 ergic agent in, 616
Alzheimer’s disease. See Dementia of the serotonergic agents in, 617
Alzheimer’s type (DAT). suicide rates with, 615-616
Alzheimer’s Disease Assessment Scale suicidal ideation and, intensification of,
(ADAS), 30, 32 654-655
Amantadine, in Parkinson’s disease, toxicity of, as suicide risk factor, 618-619
783-784 Anti-free radicals, for dementia of
Amish study, of suicide risk, affective Alzheimer’s type, 86-87
disorders and family pedigrees, Antihistamines, in geriatric patients, for
599-600 anxiety disorders, 146
Amitryptiline, in adolescents, response to, Anti-inflammatory drugs, for dementia of
651-652 Alzheimer’s type, 86-87
966 CUMULATIVE INDEX 1997
Anti-inflammatory drugs (Continued) late-life, in DSM-IV, 7
in Sydenham’s chorea, 816-817 obsessive-compulsive disorder and, 868
Antipsychotic drugs, dopamine receptors Anxiolytic agents, in obsessive-compulsive
and, 716-717 disorder, 873-874
for pathologic aggression, 432-433, 437- Anxiolytics, for agitation in dementia, 238
439 APOE. See Apolipoprotein E (APOE).
adjunctive agents and, 438-439 Apolipoprotein E (APOE), in dementia of
in obsessive-compulsive disorder, 873 Alzheimer’s type, 63-65, 84
in Sydenham’s chorea, 817 Apomorphine, in Parkinson's disease, 783
selectivity of action of, nucleus accum- Apomorphine probe, in studies of suicidal
bens and, 902-903 behavior, 573-574
Antisocial behavior, adult, childhood APP. See Amyloid precursor protein (APP).
aggression and, 288-289 Arginine vasopressin, impulsive
arousal levels and, 383-384 aggression and, 399
covert, 286 serotonin interaction with, 400
development of, parental monitoring Arousal, antisocial behavior and, 383-384
and, 291-292 emotional, cortisol reactivity in, 386-387
transactional perspective on, 296-297 psychophysiologic, aggression and, 383-
emotionality, emotion regulation, and ag-
gression, 385-388 Arrest rates, among discharged psychiatric
heart rate and, 380-381 patients, 406—407
skin conductance activity and, 376-380 ASP. See Antisocial personality (ASP).
startle potential and, 385-386 Assault, by psychiatric patient, legal issues
Antisocial personality (ASP), arrest rates in, 479
in, post discharge, 407 Attention deficit disorder, in children and
homicide and, 409 adolescents, psychopharmacotherapy
interaction of antisocial personality diath- for, 436-437
esis-adverse home environment, Attention deficit/hyperactivity disorder
308-311 (ADHD), in Sydenham’s chorea,
Antisocial personality disorder, pathologic 815-816
aggression in, lithium for, 441 Attributions, of batterers, 342-343
Anxiety, affective disorders with, violent Autism, pathologic aggression in,
behavior in, 412 psychopharmacotherapy for, 438
generalized, 734 Aversive techniques, in behavior therapy,
5-HT ascending pathways and, 735 463-464
5-HT in, 728 Azapirones, activity of, in generalized
in Huntington’s disease, 801 anxiety disorder, 734
late-life, prevalence in primary care, 5-HT»2,/2c and, down-regulation of, 734
244-245
Anxiety disorder(s), acute anxiety, in drug
toxicity, 178-179
and insomnia in geriatric patients, 137- Baclofen, in dystonia, generalized, 830
164 Basal ganglia, abnormalities of, in
in geriatric patients, acute stress disor- schizophrenia, future directions in,
der, 140 906
behavioral therapy for, 146 anatomy of and terminology, 934
clinical features of, 137-138 behavioral analysis and neuroethology
epidemiology of, 138-139 and, 946-947
grief and, 141 chemical neuroanatomy of, 695
medical condition and, 140-141 cholinergic systems in, 695-696
medical illness-associated, 177-179 dopaminergic systems in, 696-697
obsessive compulsive disorder, 139 GABAergic systems in, 697-698
panic disorder, 138-139 growth factors in, 699-700
pharmacotherapy for, 142-146 neuropeptides in, 699
phobias, 139 proteins in, 699
post-traumatic stress disorder, 139-140 connections of, 698
psychotherapy for, 146 definition of, 691
substance-induced, 140-141 disorders of, surgical interventions in,
with depression, 140-141 956
in substance withdrawal, 179 dopamine in, 935
CUMULATIVE INDEX 1997 967
dysfunction of, in obsessive-compulsive controversies and directions in, 945-
disorder, 935-936 961
neurobiology of psychosis and, 905- schizophrenia and psychosis and, 897-
906 910. See also Schizophrenia.
executive function of, 949-950 striatum and, 934-935
in depression, clinical and treatment per- structural abnormalities of, in primary
spectives, 892 major depression, 887-889
functional neuroimaging studies of computed tomography scans in,
metabolism and blood flow, 889 887-888
activation studies in, 890 magnetic resonance imaging stud-
positron emission tomography, 889- ies, 888-889
890 neuropathologic studies of, 887
single photon emission computed to- in schizophrenia, post-mortem and in
mography, 889 vivo imaging findings, 899-900
in vivo neurochemical studies, mag- surgery of, effects of, 955-956
netic resonance spectroscopy, 891 Basal ganglia circuits, direct versus
treatment response effects on regional indirect pathway of, in activation and
metabolism and blood flow, 890- inhibition of movement, 948-949
891 Basal ganglia-thalamocortical circuits,
in formation of motor pattern genera- biochemical hypotheses and, 891-892
tors, 950 Battered women’s shelters, evaluation
in modification of motor programs, 950 research in, 364
in motor sequence activation, models Batterers, alcohol/drug use of, 343
for, 947 anger and hostility in, 340-341
in movement disorders, 935 approval of violence by, 341
in pathophysiology, of obsessive-compul- blaming by, 342-343
sive disorder, 846 cognitions and attributions of, 341-343
of Tourette’s syndrome, 845-846 depression in, 340
in Sydenham’s chorea, 813 differences among, 330-331, 338-339,
inhibitory output effect, on motor pat- 339
tern generators, 948 emotional aggression in, 341
input pathways to, 934-935 expectations of, relational, 342
integration of abnormalities with bio- sex role, 341-342
chemical hypotheses, in mood disor- personality disorders in, 343-344
ders, 891-892 Type 1, 339, 341
limbic system and, in goal attainment, Type 2, 339
950-951 versus nonviolent men, psychopatho-
incentive-related signals from, 950 logic factors and, 338-345
major depression and. See Major depres- violence in family of origin, 344-345
sion, basal ganglia and. Battering, definition of, 353
memory and, 950 incidence of, 354
movement disorders of, onset delay ver- Battering relationships. See also Batterers.
sus initiation failure in, 948 communication patterns in, 347
neuroanatomy and neurochemistry of, couple distress in, 346
functional, 947-951 course of, 346
neuroanatomy of, 691-704 negative affect in, 346-347
closed loop circuits in, 693-694 psychological abuse in, 347-348
substantia nigra pars compacta, versus nonviolent relationships, 345-348
693-694 Behavior, adaptive, cortico-striatal circuits
subthalamic nucleus in, 693-694 in, 954
cortico-striatal projections in, 692-693 assessment of, for dementia of
anatomofunction link in, 692 Alzheimer’s type, 31, 39-40
striatofugal projections, 693 disturbances in, in Sydenham’s chorea,
striatum, limbic-associative, 692 812
motor, 692 homicidal. See Homicidal behavior.
thalamopetal connections (output to past, in violence prediction, 324-325
thalamus), 694-695 suicidal. See Suicidal behavior.
neurologic diseases of, depression associ- violent. See Violent behavior.
ated with, 886-887 Behavior problems, geriatric. See also
research in, applications of, 953-954 Agitation; Dementia.
968 CUMULATIVE INDEX 1997
Behavior problems (Continued) in Huntington's disease, 433-434
agitation and dementia, 227-230 Borderline personality disorder, pathologic
behavioral interventions for, 233-234 aggression in, psychopharma-
diagnosis of causes of, 230-232 cotherapy for, 441-442
environmental modification for, 234 suicide risk in, 621
family teaching and counseling for, Borderline personality organization (BPO),
234 in battering, 344
in dementia, 226-227 BoTx injections, in dystonia, focal, 831-832
management of, 225-240 generalized, 831
pharmacotherapy for, 235-238 BPO (borderline personality organization),
treatment plan for, 232 in battering, 344
Behavior therapy(ies), in obsessive- Bradykinesia, in Parkinson's disease, 775
compulsive disorder, 874-875 Brain injury, pathologic aggression
in Tourette’s syndrome, 854 following, psychopharmacotherapy
with aggressive and violent patients, ac- for, 434
celerative techniques, 462-463 psychostimulants for, 434
antecedent events, behaviors, conse- Brain lesions, impulsive aggressive
quences analysis in, 462 behavior and, 396
aversive procedures, 463-464 Brainstem, in dystonia, 828-829
contingent restraint, 464 of suicides, dorsal raphe nucleus in,
decelerative techniques, 463
585-587
Behavioral excess, amphetamine
cortical targets of, 585
microinjection precipitation of,
nuclear subdivisions of, 584-585
946-947
projection from, serotonergic, 585
Beliefs, delusional, violence risk with, 475
serotonergic innervation of cerebral
Benton Visual Retention Test-Revised, 30,
cortex and
35
Benzodiazepines, for agitation in noradrenergic system in, 587-588
dementia, 238 serotonergic system in, 582-584
for pathologic aggression, in dementia, Bromocriptine, in Parkinson's disease, 783
433 Bullying Scale for the Parent Symptom
in geriatric patients, effect of, 215 rating, 303
for anxiety disorders, 142-144 Buspirone, anxiolytic effect of, via 5-HT,,
for delirium, 103-105 receptor stimulation, 733-734
for insomnia, 155-157 as probe, in studies of suicidal behavior,
side effects of, 143-144 572
tolerance, dependence, habituation for agitation in dementia, 238
and, 144 for anger and irritability, in premen-
Bipolar disorder, impulsive aggression and strual dysphoric disorder, 441
anger in, psychopharmacotherapy for, for pathologic aggression, in mentally re-
440 tarded patients, 436
in the elderly, 121-136 post brain injury, 434
course of episodes in, 125-126 in geriatric patients, for anxiety disor-
diagnosis and nosology of, 122 ders, 144-145
epidemiology of, 122-123 for obsessive-compulsive disorder, 142
late-life recurrence of early-onset, 121- in obsessive-compulsive disorder, 873
128 Buss-Durkee Hostility Inventory, 430, 458
outcomes of, 126
pathogenesis and pathophysiology of,
123
pharmacotherapy for, 126-128, 133 a-Calcium-calmodulin-dependent kinase II
psychopathology of, 123-125 (a-CaMKIl), aggression and violent
suicide risk in, 620-621 behavior and, neurochemical and
Blaming, by batterers, 342-343 molecular studies of, 318-319
Blessing Rating Instruments, for dementia California Verbal Learning Test (CVLT),
of the Alzheimer type, 30, 32 30, 34-35
B-Blockers, for agitation in dementia, 238 performance in subcortical dementias,
for anxiety disorders, in geriatric pa- 925
tients, 145-146 subcortical dementias, 925
for pathologic aggression, in dementia, Cancer, in geriatric patients, psychiatric
433 syndromes in, 180
CUMULATIVE INDEX 1997 969
Capsulotomy, anterior, 875 posttraumatic stress reactions of, 359-
in obsessive-compulsive disorder, 940 360
Carbamazepine, for pathologic aggression, resilience of, in response to trauma
in borderline personality disorder, 442 and, 360-361
in children and adolescents, 437 stressors of, 360
in mentally retarded patients, 436 trauma and, 359-361
in seizure disorder, 435 treatment programs for, 364-365
in depression, suicidal, 622 evaluation research in, 364-365
in Sydenham’s chorea, 817 suicide in, concepts of causality in, 553-
Cardiovascular disease, psychiatric 554
syndromes in, 179-180 problem-solving effectiveness and, 554
Catecholamines, as probes, in studies of self-esteem deficits and, 554-555
suicidal behavior, 573-574 Cholinergic system, aging and,
CBA. See Cost-benefit analysis (CBA). pharmacodynamics of, 213-214
CBCL (Child Behavior Checklist), 303 neuroanatomy of, 695-696
CBT. See Cognitive behavioral therapy (CBT). interneurons in, 695-696
CCCE. See Cross-Cultural Cognitive synapses in, 696
Examination (CCCE). Cimetidine, psychiatric symptoms from, in
CDRS. See Clinical Dementia Rating Scale geriatric patients, 184-185
(CDRS). Cingulotomy, in obsessive-compulsive
CEA. See Cost-effectiveness analysis (CEA). disorder, 938-939
Central nervous system, pathways of, stereotactic, 875, 938
reciprocal, 575 Cingulum, in obsessive-compulsive
tumors of, psychiatric syndromes in, 181 disorder, 936-937
CERAD (Consortium to Establish a Circadian rhythm sleep disorders, late-life,
Registry for Alzheimer’s Disease), 31, in DSM-IV, 11
36 Citalopram, aggression reduction with,
Child abuse, child neglect versus, 480-481 398-399
legal issues in, 480-481 for pathologic aggression, in schizophre-
mandatory reporting of, 481 nia and psychoses, 439
of children of battered women, 358-369 Cities, violence in, 276, 278
parental, childhood suicide and, 557 Clincoeconomics, future of health care
violence and, 280 and, 206-207
Clinical Dementia Rating Scale (CDRS), 47
Child Behavior Checklist (CBCL), 303
in staging of dementia of Alzheimer’s
Child neglect, versus child abuse, 480-481
type, 31, 37-38
Child sexual abuse, 480-481
Clinicoeconomics, definition of, 190
Children, aggression in, family influence
history of, 190-191
on, 289-292, 295-296
in geropsychiatry, 189-210
proactive versus reactive, 295
direct and indirect costs and, 198-200
aggressive and violent behaviors in,
economic analyses in, full, 194-196
crime records of, 303, 305
partial, 193
evaluation questionnaire for, 303-304 effectiveness in, 198
observation, 303, 305 efficacy in, 197-198
sibling studies of, 304 nonpharmacologic diagnostic and treat-
aggressive conduct disorder in, patho- ment modalities and, 192-193
logic aggression in, psychopharma- pharmacoeconomics and, 191-192
cotherapy for, 436-437 Clomipramine, as probe, in studies of
attention deficit disorder in, pathologic suicidal behavior, 572
aggression in, psychopharmacother- for pathologic aggression, in autistic dis-
apy for, 436-437 order, 438
domestic violence and, effect on, 345 in obsessive-compulsive disorder, 873
health of, mental and physical, effect of Clonazepam, for insomnia, in geriatric
intimate partner violence on, 353- patients, 155
374 in obsessive-compulsive disorder, 873-
of battered women, abused, 358-359 874
effects on, children’s description of, Clonidine, as probe, in studies of suicidal
362-363 behavior, 573
developmental differences in, 363 for agitation in dementia, 238
mother-report of, 362 for pathologic aggression, in autistic dis-
of domestic violence, 361-363 order, 438
970 CUMULATIVE INDEX 1997
Clonidine (Continued) Consortium to Establish a Registry for
in Tourette’s syndrome, 854 Alzheimer’s Disease (CERAD),
Clozapine, D, receptor and, 718 assessment protocol of, 31, 36
for pathologic aggression, in borderline Contempt and belligerence, in batterers,
personality disorder, 441 341, 346
in mentally retarded patients, 435 Control, batterers and, 339
in schizophrenia and psychoses, 439 Convulsions, in Sydenham’s chorea, 812
post brain injury, 435 Cooke-Medley Hostility Scale, 430, 459
Cognition, age-related changes in, 20-22, Corcito-striato-thalamocortical (CSTC)
26 circuits, in pathophysiology, of
age-related decline in, 4, 13 Tourette’s syndrome /obsessive-
alterations in, in Parkinson's disease, 776 compulsive disorder, 846
in batterers, 341-343 Cortical-basal ganglionic degeneration,
in prepubertal children, suicide and, Parkinson's disease versus, 780
553-555 Cortico-basal ganglia circuits, in
Cognitive behavior therapy, in geriatric schizophrenia, neuropsycholocial
patients, for anxiety, 146 deficits and, 904-905
Cognitive behavioral therapy (CBT), in Corticosteroids, in Sydenham’s chorea, 817
Cortico-striatal behavior, transcranial
suicidal patients, adult studies of,
magnetic stimulation studies of, 955
649-650
Cortico-striatal circuits, affective-
adolescent subgroup in, 649-650
motivational, 744
Cognitive functions, comparison of
cognitive functions of, 745
subcortical dementias and
functional anatomy of, 743-745
Alzheimer’s disease, executive
in adaptive behaviors, 954
functioning, 923
in obsessive-compulsive disorder, 954-
language, 922-923
955
memory, 923-924
motor role of, 745
visuospatial ability, 923 sensorimotor, 744
frontal striatal system in, 920-921 structural elements of, 744
Cognitive impairment, late-life, in manic ventral cognitive, 744
patients, 126 Cortisol, in emotional arousal, 386
Cognitive therapy, in Tourette’s syndrome, Cost, of domestic violence, 366
854 of violence, economic, 277-278, 366
Cognitive-behavioral therapy, with psychological, 277
aggressive and violent patients, Cost-benefit analysis (CBA), in
464465 clinicoeconomics, 194
Cogwheel rigidity, in Parkinson’s disease, Cost-effectiveness analysis (CEA), in
775 clinicoeconomics, 194-195
Communication, in battering relationships, Cost-minimization analysis, in
346-347 clinicoeconomics, 194
Community, psychiatric disorders in, Cost-utility analysis (CUA), in
violence interrelationship with, clinicoeconomics, 194-196
411-413 Countertransference, aggressive and
Epidemiologic Catchment Area violent patients and, consultation in,
study of, 411-413 460-461
fears in, 459-450
Psychiatric Epidemiology Research
Couple distress, in battering relationships,
Interview in, 413-414
Community hospital system, for-profit
negative attributions in, 342-343
hospital chains and, 205-206
Couples therapy, for aggression and
Community outreach, in suicide violence, 466
prevention, 678-679 Criminal charges, for assault by patient,
Comorbidity, in attempted suicide, in 479
adolescents, 643 Crisis intervention(s), in suicidal patients
Computed tomography (CT), in with schizophrenia, hospitalization,
Huntington’s disease, 798 633
of brain topography, 742 nonhospitalization, 633-636
Conflict Tactics Scale, 430, 459 Crisis services, for suicidal patient with
Confusion, acute state of, delirium versus, schizophrenia, cost-effectiveness of,
in geriatric patients, 94 635
CUMULATIVE INDEX 1997 971
day treatment programs, 635 in geriatric patients, medical illness-in-
effectiveness of, 635 duced, 173-174
mobile outreach teams, 634 persecutory, violence risk with, 475
psychiatric or medical emergency Dementia of the Alzheimer type (DAT),
rooms, 633-634 APOE polymorphisms in, 63-65
short-term residential programs, assessment in, measures for, 28-40
634-635 role of, 28
Cross-Cultural Cognitive Examination atypical presentations of, 81-82
(CCCE), 33 autopsy confirmation of, 81
CUA, Cost-utilization analysis (CUA) behavioral assessments for, 31, 39-40
Culture, aging and, 16-17 brief screening measures for, 29-34
CVLT (California Verbal Learning Test), in comparison with full battery mea-
subcortical dementias, 925 sures, 34
Cyclic antidepressants, in obsessive- clinical symptomology and natural his-
compulsive disorder, 872-873 tory of, 80-82
CYP. See Cytochrome P450 (CYP) system. cognitive deterioration in, 80-81
Cytochrome P450 (CYP) system, drug course of, 51
metabolism and, 217 current advances in, 77-89
in drug-drug interactions, 219-221 diagnosis and, 79-80
versus diagnosis of psychiatric disor-
ders, 80
pathophysiology and, 82-85
Day treatment programs, for suicidal treatment and, 85-87
patient, with schizophrenia, 635 full battery measures for, 31, 35-37
Delirium, anticholinergic drug-induced, brief screening measures versus, 34
184 genetics of, amyloid precursor protein
criteria for, 170 mutations and, 62
features associated with, 170 environment and, 64-66
in dementia, diagnosis of causes of, 231- family and twin studies, 59-60
232 for susceptibility to, 66
in the elderly, 91-110 genes identified for, 61-65
clinical presentation of, 92-94 PS-1 and PS-2 mutations and poly-
diagnosis and assessment of, 94-99 morphisms, 62-63
electroencephalography in, 93, 96-98, global staging measures for, 31, 37-38
100 historical background of, 78-79
epidemiology of, 92 instruments to assess daily functioning
etiology of, 99-100 level, 31, 38-39
laboratory evaluation of, 98-99 memory impairment in, stages of, 26-28
management algorithm for, 102 memory measures for, 30, 33-35
medical illness-induced, 170-172 neuropsychological testing and assess-
neuropsychological testing and, 96 ment scales for, 25-43
nonpharmacologic management of, noncognitive symptoms of, 81
102-103 presentation of, 50
pathophysiology of, 100-101 risk estimation for, clinical APOE in, 67
pharmacotherapy for, 103-105 staging of, 51-52
physical examination in, 95 Dementia Questionnaire, 47
prevalence of, 170-171 Dementia(s). See also Dementia of the
prevention of, 106 Alzheimer type (DAT).
prognosis of, 105-106, 171 agitation in, 225-226
risk factors for, 92 behavior disturbances in, definition and
structured interview and instruments description of, 226-227
and, 95 delirium and, 183
treatment of, definitive versus pallia- diagnosis of, clinical process of, 46-48
tive, 102 complaint in, 46
versus acute confusional state, 94 history in, 46-47
late-life, in DSM-IV, 2-3 laboratory evaluation in, 47-48
Delusional ideation, in manic episodes, mental state examination in, 47
late-life versus younger patients, 124 physical and neurologic examinations
Delusions, dopaminergic drug-related, 786 in, 47
homicide and, 410 differential diagnosis of, 45-57
972 CUMULATIVE INDEX 1997
Dementia(s) (Continued) prevention of, psychoeducation of
decision tree for, 48-50 patient, family, public, 620
in DSM-IV, 4-5 suicide risk in, 614-615
teaching families and caregivers for, medication-induced, 184
52-53 obsessive-compulsive disorder and, 868-
frontal lobe, 69, 82 869
genetics of, 59-76 post infarct, cortical and subcortical, 886
in Alzheimer’s disease. See Dementia suicidal, psychopharmacology of, future
of the Alzheimer type (DAT). role of, 621-622
in DSM-IV, 3-5 suicide risk in, genetics and, 598-599
in Huntington's disease, 794-795 suicide /homicide risk in, 476
in manic patients, 126 treatment of, choices for, 614
in Parkinson's disease, 776-777 failure to seek, 613-614
Lewy body, 777 unipolar, as suicide risk, in elderly, 673
subcortical, 776-777 hostility and anger in, psychopharma-
Lewy body, 69 cotherapy for, 440
pathologic aggression in, psychopharma- Desipramine probe, in studies of suicidal
cotherpy for, 432-433 behavior, 573
Pick’s disease, 69 Developmentally disabled persons, abuse
prevalence in primary care, 245-246 of, legal issues in, 481-482
subcortical. See Subcortical dementia(s). Dexamethasone suppression, in studies of
vascular, 67-68 suicide, 565-566
Depression. See also Major depressive Dextroamphetamine, for attention deficit
disorder (MDD). disorder, 436-437
confounding effect of, in neuroendocri- Diabetes mellitus, in geriatric patients,
nologic studies of suicide, 565 psychiatric syndromes in, 182
gene for, suicidal behavior and, 602 Diagnostic and Statistical Manual of
5-HT ascending pathways and, 735 Mental Disorders, ed 4 (DSM-IV), late-
in battered women, 356 life psychiatric diagnosis in, 1-14
in elderly versus versus young patients, Digit Span tests, performance in
111 subcortical dementias, 924
chronicity of, 114-115 Digoxin, psychiatric symptoms from, in
prevalence and incidence of, 112-114 geriatric patientss, 184
psychological causes of, 117 Diphenhydramine, for insomnia, in
symptoms in, 112 geriatric patients, 159
treatment response in, 115-116 Diphenylhydantoin, for pathologic
in geriatric patients, indirect versus di- aggression, in children and
rect costs of treatment in, 199-200 adolescents, 437
medical illness-associated, 174-176 Discipline, maternal, influence on
in Huntington’s disease, 795-796, 801, children’s aggression, 295-296
886-887 Disruptive disorders, in children, suicide
in Parkinson's disease, 777-778, 784-785, and, 555
886 Dissociative disorders, late-life, in DSM-IV,
in violent verus nonviolent men, 340 9
late-life, diagnosis in primary care, 246- Distribution, of drug, aging and, 216-219
248 Divalproex sodium, in depression,
criteria used for, 249-250 suicidal, 622
in anxiety, 140-141 Domestic violence. See also Batterers;
myths and misconceptions of, 111-119 Battering relationships.
prevalence in primary care, 244 communication patterns and, 347
recognition of, 673-675 consequences of, 337
screening for, 251-253 correlation with violence in family of ori-
clinical outcome and, 253 gin, 330-332
treatment of, 675-676 cost of health care for, 366
major, in schizophrenia, suicidal behav- couple distress in, 338, 346
ior and, 629 effects of, on children, 361-363
suicidal behavior in, electroconvulsive historical perspective on, 337-338
therapy for, 619-620 male batterers in, demographic character-
suicide in, family history of suicide istics of, 329-332
and, 597 recidivism of, 331